Parallel Advisors LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,164 shares of the biopharmaceutical company's stock after selling 2,876 shares during the quarter. Parallel Advisors LLC's holdings in Gilead Sciences were worth $3,828,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of GILD. Brighton Jones LLC lifted its stake in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after acquiring an additional 2,450 shares during the period. Strategic Blueprint LLC lifted its position in Gilead Sciences by 7.5% during the fourth quarter. Strategic Blueprint LLC now owns 2,750 shares of the biopharmaceutical company's stock valued at $254,000 after purchasing an additional 192 shares during the period. Foster & Motley Inc. boosted its holdings in Gilead Sciences by 80.4% in the fourth quarter. Foster & Motley Inc. now owns 10,587 shares of the biopharmaceutical company's stock worth $978,000 after purchasing an additional 4,718 shares during the last quarter. OLD National Bancorp IN grew its position in Gilead Sciences by 5.2% in the 4th quarter. OLD National Bancorp IN now owns 17,395 shares of the biopharmaceutical company's stock worth $1,607,000 after purchasing an additional 857 shares during the period. Finally, Crews Bank & Trust bought a new position in shares of Gilead Sciences during the 4th quarter valued at $31,000. Hedge funds and other institutional investors own 83.67% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts recently commented on GILD shares. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research note on Thursday, February 13th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Finally, Morgan Stanley boosted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $110.55.
Read Our Latest Analysis on GILD
Insiders Place Their Bets
In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares in the company, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the sale, the chief executive officer now directly owns 620,268 shares in the company, valued at $68,489,992.56. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 60,929 shares of company stock worth $6,748,980 over the last 90 days. Company insiders own 0.27% of the company's stock.
Gilead Sciences Price Performance
Shares of Gilead Sciences stock traded up $0.16 during trading hours on Wednesday, reaching $109.49. The company's stock had a trading volume of 2,672,304 shares, compared to its average volume of 7,709,869. The firm has a 50 day moving average price of $105.45 and a 200-day moving average price of $101.10. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The stock has a market cap of $136.20 billion, a P/E ratio of 295.92, a P/E/G ratio of 0.71 and a beta of 0.26.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.32) earnings per share. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.89%. The ex-dividend date is Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Stories
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
